het onderzoek is van algemeen cognitief-psychologische aard en heeft geen betrekking op stoornissen of aandoeningen. niet van toepassing
Conditions
Interventions
Clonidine, 150 µg, single dose, administration p.o. in a capsule. Clonidine is
a centrally acting adrenergic alpha-2 agonist that is used mainly as an
antihypertensive drug, as well as a maintenance
Keränen et al., 1978).The usual
maintenance dose for antihypertensive indications is between 0.075 and 0.15 mg
thrice a day
for migraine indications, usual maintenance doses are between
0.025 mg and 0.075 mg twice a day. We intend to administer a single oral dose
of 0.2 mg clonidine, the most widely used dose in psychoph
Coull et al., 2001
Smith et al., 2003).
Because of the anti-hypertensive properties of clonidine, heart rate and blood
pressure will be monitored for subject safety. Measurements will be taken just
prior to ingestion
Sponsors
Universiteit Leiden
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult participants between 18 and 30 years old, with no history of neurological disorder, hypotension, or glaucoma will be included in this study. All participants will be native Dutch speakers.
Exclusion criteria
Exclusion criteria: Exclusion criteria are: hypotension, bradycardia, cardiac arrhythmia, severe pulmonary conditions, head trauma, learning disabilities, pregnancy, alcoholism or substance abuse, glaucoma, renal failure or hepatic insufficiency, or use of (psychotropic) medication that may affect the central nervous system. Smokers will be excluded because of the effects of nicotine on the cholinergic system. A heart rate of less than 60 beats per minute and/or a blood pressure lower than 100/60 mmHg will lead to exclusion prior to the test phase. For safety reasons (i.e. to ensure optimal communication between participants and experimenter), only native Dutch speakers will be included as participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are cognitive task performance as reflected by reaction times and error rates, in addition to EEG measurements. The endpoints are the modulatory effects of clonidine and scopolamine relative to placebo on the main study parameters. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters are individual differences as operationalised by genotyped polymorphisms and participants* scores on personality questionnaires. The endpoints are correlations and statistical analyses with the results from the genetic analyses and with questionnaire scores. | — |
Countries
Netherlands
Outcome results
None listed